Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L.
cytomegalovirus
glycoprotein O
hyperimmune globulin
immune evasion
neutralizing antibody
polymorphism
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
09 07 2022
09 07 2022
Historique:
received:
13
06
2022
revised:
05
07
2022
accepted:
06
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Human cytomegalovirus (CMV) utilizes different glycoproteins to enter into fibroblast and epithelial cells. A trimer of glycoproteins H, L, and O (gH/gL/gO) is required for entry into all cells, whereas a pentamer of gH/gL/UL128/UL130/UL131A is selectively required for infection of epithelial, endothelial, and some myeloid-lineage cells, but not of fibroblasts. Both complexes are of considerable interest for vaccine and immunotherapeutic development but present a conundrum: gH/gL-specific antibodies have moderate potency yet neutralize CMV entry into all cell types, whereas pentamer-specific antibodies are more potent but do not block fibroblast infection. Which cell types and neutralizing activities are important for protective efficacy
Identifiants
pubmed: 35891489
pii: v14071508
doi: 10.3390/v14071508
pmc: PMC9323020
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Epitopes
0
Membrane Glycoproteins
0
Viral Envelope Proteins
0
glycoprotein H, Cytomegalovirus
0
glycoprotein O, cytomegalovirus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI128912
Pays : United States
Organisme : NIH HHS
ID : R01AI128912
Pays : United States
Organisme : Austrian Science Fund FWF
ID : P26420-B13
Pays : Austria
Références
Arch Virol. 2011 Dec;156(12):2145-55
pubmed: 21938463
Rev Med Virol. 2007 Sep-Oct;17(5):355-63
pubmed: 17542052
J Virol. 1990 Mar;64(3):1079-85
pubmed: 2154594
J Virol. 2016 Jun 24;90(14):6216-6223
pubmed: 27122579
J Virol. 2014 Jan;88(1):403-16
pubmed: 24155395
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17965-70
pubmed: 25453106
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8
pubmed: 16319222
Clin Microbiol Rev. 2013 Jan;26(1):86-102
pubmed: 23297260
Cell. 2021 Mar 4;184(5):1232-1244.e16
pubmed: 33626330
Lancet. 1998 Oct 17;352(9136):1280-1
pubmed: 9788461
Science. 2010 Apr 2;328(5974):102-6
pubmed: 20360110
PLoS Pathog. 2018 Dec 3;14(12):e1007452
pubmed: 30507948
J Virol. 2012 Jul;86(13):7444-7
pubmed: 22532696
J Virol. 2002 Nov;76(21):10841-8
pubmed: 12368327
Antiviral Res. 2013 Oct;100(1):151-8
pubmed: 23933116
Pediatrics. 1999 Jul;104(1 Pt 1):55-60
pubmed: 10390260
Virology. 1993 Apr;193(2):834-41
pubmed: 8384757
Clin Vaccine Immunol. 2012 Jun;19(6):909-13
pubmed: 22492744
J Virol. 2021 Aug 25;95(18):e0065721
pubmed: 34160252
J Virol. 2017 Jun 9;91(13):
pubmed: 28381568
J Virol. 2017 Mar 13;91(7):
pubmed: 28077654
J Gen Virol. 1993 Feb;74 ( Pt 2):255-64
pubmed: 8381465
J Virol. 2006 Jan;80(2):710-22
pubmed: 16378974
J Pediatric Infect Dis Soc. 2014 Sep;3 Suppl 1:S2-6
pubmed: 25232473
Clin Infect Dis. 2006 Oct 15;43(8):994-1000
pubmed: 16983610
N Engl J Med. 2001 May 3;344(18):1366-71
pubmed: 11333993
J Virol. 2020 Mar 31;94(8):
pubmed: 31996433
Sci Adv. 2022 Mar 11;8(10):eabm2546
pubmed: 35275718
J Gen Virol. 2008 Feb;89(Pt 2):359-368
pubmed: 18198366
N Engl J Med. 1973 Jul 5;289(1):1-5
pubmed: 4350775
J Virol. 2006 May;80(9):4591-600
pubmed: 16611919
J Virol. 2017 Jul 12;91(15):
pubmed: 28490582
PLoS Pathog. 2012;8(10):e1002999
pubmed: 23133379
J Virol. 2020 Jul 1;94(14):
pubmed: 32350071
Microbiol Mol Biol Rev. 2016 Jun 15;80(3):663-77
pubmed: 27307580
Curr Opin Virol. 2016 Jun;18:1-8
pubmed: 26849495
Vaccine. 2009 Mar 4;27(10):1540-8
pubmed: 19168107
Front Microbiol. 2017 Aug 22;8:1609
pubmed: 28878758
Nat Microbiol. 2016 Jun 06;1(8):16082
pubmed: 27573107
Sci Immunol. 2017 Jun 30;2(12):
pubmed: 28783665
J Virol. 2010 Mar;84(5):2585-96
pubmed: 20032184
J Virol. 2010 Jan;84(2):1005-13
pubmed: 19889756
Clin Microbiol Rev. 2010 Oct;23(4):689-712
pubmed: 20930070
Euro Surveill. 2009 Mar 05;14(9):26-32
pubmed: 19317969
Sci Adv. 2021 Mar 5;7(10):
pubmed: 33674318
N Engl J Med. 1977 Jun 2;296(22):1254-8
pubmed: 193004
Antimicrob Agents Chemother. 2015 Mar;59(3):1558-68
pubmed: 25534746
Nucleic Acids Res. 2005 Feb 24;33(4):e36
pubmed: 15731329
J Biomed Biotechnol. 2012;2012:428498
pubmed: 22187535
PLoS Pathog. 2011 Jan 13;7(1):e1001256
pubmed: 21249233
Virology. 2002 Feb 15;293(2):281-94
pubmed: 11886248
Vaccine. 2011 Mar 24;29(15):2705-11
pubmed: 21310190
Vaccine. 2007 Apr 30;25(17):3319-27
pubmed: 17287056
Rev Med Virol. 2011 Jul;21(4):240-55
pubmed: 21674676
J Infect Dis. 1981 Mar;143(3):391-5
pubmed: 6262413
Trends Cell Biol. 2004 Jan;14(1):5-8
pubmed: 14729174
J Virol. 2015 Sep;89(17):8999-9009
pubmed: 26085146
Expert Opin Pharmacother. 2001 Aug;2(8):1247-57
pubmed: 11584992
Vaccine. 1991 Sep;9(9):631-7
pubmed: 1659051
mBio. 2013 Jun 04;4(3):e00332-13
pubmed: 23736286
Rev Infect Dis. 1990 Sep-Oct;12 Suppl 7:S754-66
pubmed: 2173105
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4997-5005
pubmed: 24297878
Am J Pathol. 2010 Sep;177(3):1298-310
pubmed: 20651234
Prenat Diagn. 2008 Jun;28(6):512-7
pubmed: 18509871
Vaccine. 2008 Oct 23;26(45):5760-6
pubmed: 18718497
J Virol. 2019 May 15;93(11):
pubmed: 30894468
Virology. 2004 Jan 20;318(2):582-97
pubmed: 14972526
Rev Med Virol. 2007 Jul-Aug;17(4):253-76
pubmed: 17579921
PLoS Pathog. 2017 Apr 12;13(4):e1006281
pubmed: 28403202
Antiviral Res. 2011 Jun;90(3):151-9
pubmed: 21439328
BMC Res Notes. 2014 Nov 12;7:794
pubmed: 25392013
J Virol. 1998 Oct;72(10):8191-7
pubmed: 9733861
J Infect Dis. 1992 Feb;165(2):381-4
pubmed: 1309850